Breaking News

Agilent, Picometrics In Mass Spec Pact

By Kristin Brooks | January 17, 2014

Will provide combined solutions for CE-LIF detection

Agilent Technologies, Inc. and Picometrics Technologies have signed a co-marketing agreement to provide combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection, and mass spectrometry, to biopharmaceutical customers. The collection of tools will provide an online CE-LIF-MS solution suitable for R&D of complex large-molecule compounds.
 
“We are very pleased to extend a long-standing and fruitful partnership with Agilent and consolidate our development strategy,” said Jean Charles Garcia, president of Picometrics. “This unique technological platform using our new-generation LIF detection will significantly increase efficiency for biotherapeutic characterization in research, development and quality control.”
 
“We are excited to collaborate with Picometrics and provide this unique product offering to the biopharmaceutical industry—particularly those focusing on the research and development of NBEs, or new biological entities,” said Michael Frank, Agilent marketing director, liquid phase separations. “As conventional drug research becomes outmoded in meeting the increasing demands of complex, large-molecule drug development, scientists need highly sophisticated tools like these to advance therapeutic discovery.”
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Biopharmaceutical Contract Manufacturing Capacity Expansions

    Biopharmaceutical Contract Manufacturing Capacity Expansions

    William Downey , HighTech Business Decisions||June 2, 2015
    Biopharma contract manufacturing market continues to expand, expected to grow 8% over the next five years